Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. (Q51748822)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 September 2013

Language	Label	Description	Also known as
English	Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.	scientific article published on 9 September 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

type 2 diabetes

0 references

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Michael Roden

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jianping Weng

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Jens Eilbracht

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Gabriel Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Hans J Woerle

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Uli C Broedl

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

EMPA-REG MONO trial investigators

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

9 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

The Lancet: Diabetes & Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

208-219

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The obesity paradox, weight loss, and coronary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1016%2FS2213-8587%2813%2970084-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-8587(13)70084-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24622369%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51748822&oldid=2003502631"